Equipotent doses to switch from high doses of opioids to transdermal buprenorphine

Supportive Care in Cancer

Volumn 17, Issue 6, 2009, Pages 715-718

  Mercadante, Sebastiano ^a   Casuccio, Alessandra ^a   Tirelli, Walter ^b   Giarratano, Antonello ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Hospice Sacro Cuore   (Italy)

Author keywords

Cancer pain; Opioid switching; Transdermal buprenorphine

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GROUPS BY AGE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PATIENT SATISFACTION; PROSPECTIVE STUDIES;

EID: 67349154136     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0546-6     Document Type: Article

References (10)

1. T Christoph B Kogel K Schiene E Friderichs 2005 Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain Eur J Pharmacol 507 87 98 (Pubitemid 40126844)
2. M Davis 2005 Buprenorphine in cancer pain Support Care Cancer 13 878 887 (Pubitemid 41502247)
3. E Freye A Anderson-Hillemacher I Ritzdorf JV Levy 2007 Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients Pain Pract 7 123 129 (Pubitemid 46901548)
4. GW Hanks F Conno N Cherny M Hanna E Kalso HJ McQuay S Mercadante J Meynadier P Poulain C Ripamonti L Radbruch JR Casas J Sawe RG Twycross V Ventafridda Expert Working Group of the Research Network of the European Association for Palliative Care 2001 Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 587 593 (Pubitemid 32238990)
5. R Likar B Krainer R Sittl 2008 Challenging the equipotency calculation for transdermal buprenorphine: four case studies Int J Clin Pract 62 152 156 (Pubitemid 350294004)
6. S Mercadante P Villari P Ferrera G Porzio F Aielli L Verna A Casuccio 2006 Safety and effectiveness of intravenous morphine for breakthrough pain in patients receiving transdermal buprenorphine J Pain Symptom Manage 32 175 179 (Pubitemid 44131646)
7. S Mercadante P Ferrera P Villari 2007 Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients Support Care Cancer 15 441 444 (Pubitemid 46697019)
8. S Mercadante G Porzio F Fulfaro F Aielli L Verna C Ficorella A Casuccio S Riina G Intravaia S Mangione 2007 Switching from transdermal drugs: an observational n of 1 study of fentanyl and buprenorphine J Pain Symptom Manage 34 532 538 (Pubitemid 47633900)
9. R Sittl N Griessinger R Likar 2003 Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomised, double-blind, placebo-controlled trial Clin Ther 23 150 168 (Pubitemid 36206743)
10. R Sittl R Likar B Pousen Nautrup 2005 Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non cancer pain: results of a retrospective cohort study Clin Ther 27 225 237 (Pubitemid 40462016)